Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetyl-L-carnitine plus cisplatin-containing chemotherapy in first-line advanced non-small cell lung cancer
2010-022021-15Phase 3Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Acetyl-L-carnitine + cisplatin-containing chemotherapy with Placebo + cisplatin-containing chemotherapy (2 arms). Primary endpoint: Toxicity-free survival. Started Nov 2010; status: terminated.
02
Drugs
acetyl-l-carnitine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-022021-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022021-15.